शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
KOPRANNSEKopran Limited· PharmaceuticalsHighNeutral
Announced Wed, 12 Nov, 2025 · 14:15 IST

Kopran posts consolidated loss of Rs 12.47 cr in H1 FY26 on revenue decline

Revenue declinedNet loss reportedEBITDA margin compressionResults View source PDFExplain this filing

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.8%Reaction day
₹160.39
prior close
₹161.75
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-6.7% vs market

On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-8.1
10m
-6.3
15m
-6.0
30m
-3.9
Sessions after the filingfrom the prior close
StockMarketvs market
Reaction day
-5.8+0.9-6.7
Next day
-11.0+0.8-11.8
2d
-10.5+0.7-11.3
3d
-13.1+1.3-14.4
4d
-15.2+0.5-15.7
5d
-16.8+0.4-17.2
1w
-20.1-1.5-18.6
15d
-12.7-2.4-10.2
1m
-18.3-4.4-13.9
2m
-7.8-7.2-0.6
3m
-15.3-5.0-10.3
UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kopran posted weak H1 FY26 results. Consolidated revenue fell 13% YoY to Rs 253.13 cr (vs Rs 291 cr). Standalone revenue dropped 24% to Rs 93.72 cr. Consolidated net loss of Rs 12.47 cr vs profit of Rs 18.48 cr last year. Standalone PAT turned negative at Rs 1.48 cr loss vs Rs 10.85 cr profit. Q2 consolidated loss of Rs 9.92 cr.

Likely market impact

Sharp revenue decline and swing to losses signal operational stress; Q2 weakness could pressure the stock near term.